1-3 of 3
non-hodgkin's lymphoma, indolent
Close
Sort by
Journal Articles

Phase 1/2a study of 177 Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma

Clinical Trials & Observations
Arne Kolstad, Tim Illidge, Nils Bolstad, Signe Spetalen, Ulf Madsbu, Caroline Stokke, Johan Blakkisrud, Ayca Løndalen, Noelle O'Rourke, Matthew Beasley, Wojciech Jurczak, Unn-Merete Fagerli, Michal Kaščák, Mike Bayne, Aleš Obr, Jostein Dahle, Lisa Rojkjaer, Veronique Pascal, Harald Holte
Journal: Blood Advances
Blood Adv (2020) 4 (17): 4091–4101.
https://doi.org/10.1182/bloodadvances.2020002583
Published: 2020
Includes: Supplemental data
Journal Articles

Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYA

Clinical Trials & Observations
Sarah C. Rutherford, Michael Herold, Wolfgang Hiddemann, Lale Kostakoglu, Robert Marcus, Maurizio Martelli, Laurie H. Sehn, Marek Trněný, Judith Trotman, Umberto Vitolo, Tina Nielsen, Federico Mattiello, Deniz Sahin, Gila Sellam, Peter Martin
Journal: Blood Advances
Blood Adv (2020) 4 (8): 1589–1593.
https://doi.org/10.1182/bloodadvances.2019001261
Published: 2020
Includes: Supplemental data
Journal Articles

Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma

Clinical Trials & Observations
Sven de Vos, Nina D. Wagner-Johnston, Steven E. Coutre, Ian W. Flinn, Marshall T. Schreeder, Nathan H. Fowler, Jeff P. Sharman, Ralph V. Boccia, Jacqueline C. Barrientos, Kanti R. Rai, Thomas E. Boyd, Richard R. Furman, Yeonhee Kim, Wayne R. Godfrey, John P. Leonard
Journal: Blood Advances
Blood Adv (2016) 1 (2): 122–131.
https://doi.org/10.1182/bloodadvances.2016000976
Published: 2016
Includes: Supplemental data